Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
acute myeloid leukemia
off-label
regulatory issue
relapsed/refractory
venetoclax
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Dec 2021
21 Dec 2021
Historique:
received:
19
10
2021
revised:
15
12
2021
accepted:
15
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Despite the progress in the development of new therapeutic strategies, relapsed/refractory (R/R) acute myeloid leukemia (AML) still represents a high unmet medical need. Treatment options in this setting include enrollment into clinical trials, allogeneic stem cell transplantation and/or targeted therapy. Nevertheless, it is associated with poor outcomes. Thus, the development of new treatments, which could ameliorate the prognosis of these patients with a good safety profile are highly demanded. Recently, venetoclax (VEN) has been approved for naïve AML patients unfit for intensive chemotherapy. In this regard, regimens including VEN could represent a valuable treatment option even in those with R/R disease and several studies have been conducted to demonstrate its role in this clinical setting. This review aims to summarize the current evidence on the use of VEN regimens in the treatment of R/R AML.
Identifiants
pubmed: 35008186
pii: cancers14010022
doi: 10.3390/cancers14010022
pmc: PMC8750253
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Med. 2018 Dec;24(12):1859-1866
pubmed: 30420752
Ann Hematol. 2019 Aug;98(8):1927-1932
pubmed: 31187237
Bone Marrow Transplant. 2019 Apr;54(4):620-624
pubmed: 30287936
Am J Hematol. 2018 May 17;:
pubmed: 29770480
Cell Stem Cell. 2013 Mar 7;12(3):329-41
pubmed: 23333149
Clin Cancer Res. 2016 Sep 1;22(17):4440-51
pubmed: 27103402
Cancer Discov. 2014 Mar;4(3):362-75
pubmed: 24346116
Nat Med. 2015 Feb;21(2):178-84
pubmed: 25599133
J Clin Oncol. 2021 Sep 1;39(25):2768-2778
pubmed: 34043428
Am J Hematol. 2020 Jul 6;:
pubmed: 32628327
Front Oncol. 2021 Mar 09;11:641450
pubmed: 33796467
Oncotarget. 2018 May 25;9(40):26046-26063
pubmed: 29899841
Leukemia. 2014 Aug;28(8):1657-65
pubmed: 24451410
Haematologica. 2020 Jan 23;105(11):2659-2663
pubmed: 33131256
Br J Haematol. 2021 Mar;192(6):1026-1030
pubmed: 32458446
Blood. 2015 Jul 16;126(3):363-72
pubmed: 26045609
Cancer Discov. 2019 Jul;9(7):890-909
pubmed: 31048321
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Front Immunol. 2021 Jul 06;12:661882
pubmed: 34295328
Am J Hematol. 2019 Oct;94(10):E253-E255
pubmed: 31259427
Blood. 2016 Jun 23;127(25):3215-24
pubmed: 27069256
Leuk Lymphoma. 2020 Sep;61(9):2221-2225
pubmed: 32420775
Cancer Discov. 2018 Dec;8(12):1566-1581
pubmed: 30185627
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Leukemia. 2014 Jul;28(7):1557-60
pubmed: 24531733
Front Oncol. 2021 Mar 11;11:649209
pubmed: 33777810
Hemasphere. 2021 Mar 09;5(4):e549
pubmed: 33718803
Clin Pharmacol Ther. 2017 Jan;101(1):89-98
pubmed: 27806433
Br J Clin Pharmacol. 2014 Mar;77(3):545-53
pubmed: 23919928
Blood. 2020 Jun 11;135(24):2137-2145
pubmed: 32219442
Sci Rep. 2016 Jun 10;6:27696
pubmed: 27283158
Blood. 1993 Jun 1;81(11):3091-6
pubmed: 7684624
Blood. 2009 Apr 30;113(18):4179-87
pubmed: 19008455
Lancet Oncol. 2016 Jun;17(6):768-778
pubmed: 27178240
Ann Hematol. 2021 Mar;100(3):817-824
pubmed: 33442793
J Clin Oncol. 2019 May 20;37(15):1277-1284
pubmed: 30892988
Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4
pubmed: 32822582
Lancet Haematol. 2020 Oct;7(10):e724-e736
pubmed: 32896301
Cancer Discov. 2016 Oct;6(10):1106-1117
pubmed: 27520294
Cell. 2012 Oct 12;151(2):344-55
pubmed: 23063124
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Leuk Res. 2020 Apr;91:106317
pubmed: 32092584
Am J Hematol. 2019 Feb;94(2):E48-E50
pubmed: 30431666
Front Pharmacol. 2020 Nov 30;11:621934
pubmed: 33329008
Cancer. 2021 Nov 15;127(22):4213-4220
pubmed: 34343352
Front Pharmacol. 2021 Nov 11;12:748766
pubmed: 34899303
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Front Pharmacol. 2015 Nov 18;6:280
pubmed: 26635610
Cancer Cell. 2018 Nov 12;34(5):724-740.e4
pubmed: 30423294
Leukemia. 2015 Jun;29(6):1290-300
pubmed: 25650089
Blood. 2015 Mar 26;125(13):2120-30
pubmed: 25631767
Cancer Cell. 2006 May;9(5):351-65
pubmed: 16697956
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Haematologica. 2018 Sep;103(9):e404-e407
pubmed: 29545346
Leukemia. 2014 Jan;28(1):210-2
pubmed: 23860449
Cancer Discov. 2018 Dec;8(12):1582-1597
pubmed: 30254093
Bone Marrow Transplant. 2021 Nov;56(11):2804-2812
pubmed: 34274954
Ann Hematol. 2012 Dec;91(12):1861-70
pubmed: 22893484
Blood Cancer J. 2012 Mar;2(3):e60
pubmed: 22829255
Front Pharmacol. 2020 Sep 16;11:579886
pubmed: 33041824
Curr Hematol Malig Rep. 2018 Aug;13(4):256-264
pubmed: 29982865
Leukemia. 2018 Feb;32(2):303-312
pubmed: 28751770
Am J Transl Res. 2016 Sep 15;8(9):3893-3902
pubmed: 27725868
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Blood Adv. 2021 Mar 9;5(5):1552-1564
pubmed: 33687434
Signal Transduct Target Ther. 2017 Apr 07;2:17012
pubmed: 29263915
Front Pharmacol. 2020 Aug 21;11:1307
pubmed: 32973526
Cancer Cell. 2006 Nov;10(5):375-88
pubmed: 17097560
Am J Hematol. 2020 Dec;95(12):1511-1521
pubmed: 32833294
J Clin Med. 2021 Apr 14;10(8):
pubmed: 33919958
Leuk Res. 2020 Mar;90:106314
pubmed: 32035355
J Clin Oncol. 2012 Jul 20;30(21):2670-7
pubmed: 22689805
Ann Hematol. 2020 Mar;99(3):501-511
pubmed: 31965269
Br J Haematol. 2019 Oct;187(2):e45-e48
pubmed: 31441045
Leukemia. 2019 Apr;33(4):905-917
pubmed: 30214012
Blood Cancer J. 2021 Mar 4;11(3):49
pubmed: 33664234
Ann Hematol. 2022 Jan;101(1):119-130
pubmed: 34568973
Blood. 2020 Aug 27;136(9):1023-1032
pubmed: 32518943
Am J Hematol. 2018 Mar;93(3):401-407
pubmed: 29218851
Blood. 2012 Mar 1;119(9):2114-21
pubmed: 22186996
J Clin Oncol. 2016 Mar 20;34(9):972-9
pubmed: 26811524
Cancer Manag Res. 2021 Jul 12;13:5613-5621
pubmed: 34285581
Br J Haematol. 2002 Aug;118(2):521-34
pubmed: 12139741
Blood Adv. 2021 Apr 27;5(8):2156-2164
pubmed: 33885751
Front Pharmacol. 2020 Sep 25;11:588132
pubmed: 33101042
Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193
pubmed: 30655609
Am J Hematol. 2020 Sep;95(9):1006-1014
pubmed: 32390196
Cancer Discov. 2020 Apr;10(4):536-551
pubmed: 31974170
Mol Cell. 2001 Sep;8(3):705-11
pubmed: 11583631
Cancer Med. 2020 Jun;9(12):4160-4165
pubmed: 32319737
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Ann Hematol. 2021 Apr;100(4):1111-1113
pubmed: 33175198
Leuk Lymphoma. 2015 Jan;56(1):226-9
pubmed: 24707940
Sci Rep. 2016 Oct 27;6:35907
pubmed: 27786282
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221